Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior.

Caffeine is the most widely consumed psychoactive substance in the world and presents with wide interindividual variation in metabolism. This variation may modify potential adverse or beneficial effects of caffeine on health. We conducted a genome-wide association study (GWAS) of plasma caffeine, paraxanthine, theophylline, theobromine and paraxanthine/caffeine ratio among up to 9,876 individuals of European ancestry from six population-based studies. A single SNP at 6p23 (near CD83) and several SNPs at 7p21 (near AHR), 15q24 (near CYP1A2) and 19q13.2 (near CYP2A6) met GW-significance (P < 5 × 10-8) and were associated with one or more metabolites. Variants at 7p21 and 15q24 associated with higher plasma caffeine and lower plasma paraxanthine/caffeine (slow caffeine metabolism) were previously associated with lower coffee and caffeine consumption behavior in GWAS. Variants at 19q13.2 associated with higher plasma paraxanthine/caffeine (slow paraxanthine metabolism) were also associated with lower coffee consumption in the UK Biobank (n = 94 343, P < 1.0 × 10-6). Variants at 2p24 (in GCKR), 4q22 (in ABCG2) and 7q11.23 (near POR) that were previously associated with coffee consumption in GWAS were nominally associated with plasma caffeine or its metabolites. Taken together, we have identified genetic factors contributing to variation in caffeine metabolism and confirm an important modulating role of systemic caffeine levels in dietary caffeine consumption behavior. Moreover, candidate genes identified encode proteins with important clinical functions that extend beyond caffeine metabolism.

[1]  Manolis Kellis,et al.  HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease , 2015, Nucleic Acids Res..

[2]  T. Lehtimäki,et al.  A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism , 2015, PLoS genetics.

[3]  Christina N. Lessov-Schlaggar,et al.  Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption , 2015, PloS one.

[4]  Gonçalo R. Abecasis,et al.  Minimac2: Faster Genotype Imputation , 2015, Bioinform..

[5]  M. Cornelis.  Toward systems epidemiology of coffee and health , 2015, Current opinion in lipidology.

[6]  G. Abecasis,et al.  Genetic and population analysis minimac2: faster genotype imputation , 2015 .

[7]  J. J. Wang,et al.  Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption , 2014, Molecular Psychiatry.

[8]  John P. Overington,et al.  An atlas of genetic influences on human blood metabolites , 2014, Nature Genetics.

[9]  F. Paccaud,et al.  Reference Values and Factors Associated With Renal Resistive Index in a Family-Based Population Study , 2014, Hypertension.

[10]  H. Zimdahl,et al.  International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms , 2013, Clinical pharmacology and therapeutics.

[11]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[12]  Alireza Moayyeri,et al.  COHORT PROFILE Cohort Profile : TwinsUK and Healthy Ageing Twin Study , 2013 .

[13]  M. Johannesson,et al.  The Swedish Twin Registry: Establishment of a Biobank and Other Recent Developments , 2012, Twin Research and Human Genetics.

[14]  W. Zhuo,et al.  Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy , 2012, Pharmacogenetics and genomics.

[15]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[16]  A. S. Gross,et al.  Influence of Environmental and Genetic Factors on CYP1A2 Activity in Individuals of South Asian and European Ancestry , 2012, Clinical pharmacology and therapeutics.

[17]  J. Marchini,et al.  Fast and accurate genotype imputation in genome-wide association studies through pre-phasing , 2012, Nature Genetics.

[18]  H. Raunio,et al.  CYP2A6: genetics, structure, regulation, and function , 2012, Drug metabolism and drug interactions.

[19]  R. Altman,et al.  PharmGKB summary: phenytoin pathway , 2012, Pharmacogenetics and genomics.

[20]  A. S. Gross,et al.  Measurement of CYP1A2 activity: a focus on caffeine as a probe. , 2012, Current drug metabolism.

[21]  R. Altman,et al.  PharmGKB summary: caffeine pathway , 2012, Pharmacogenetics and genomics.

[22]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for CYP1A2 , 2012, Pharmacogenetics and genomics.

[23]  C. Gieger,et al.  Human metabolic individuality in biomedical and pharmaceutical research , 2011, Nature.

[24]  W. Rathmann,et al.  Cohort profile: the study of health in Pomerania. , 2011, International journal of epidemiology.

[25]  E. Rimm,et al.  Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption , 2011, PLoS genetics.

[26]  M. Arnaud.  Pharmacokinetics and metabolism of natural methylxanthines in animal and man. , 2011, Handbook of experimental pharmacology.

[27]  M. Schwab,et al.  Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver , 2010, Front. Pharmacol..

[28]  O. Fardel,et al.  Involvement of aryl hydrocarbon receptor in basal and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced expression of target genes in primary human hepatocytes. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[29]  Ayellet V. Segrè,et al.  Common Inherited Variation in Mitochondrial Genes Is Not Enriched for Associations with Type 2 Diabetes or Related Glycemic Traits , 2010, PLoS genetics.

[30]  P. Visscher,et al.  A versatile gene-based test for genome-wide association studies. , 2010, American journal of human genetics.

[31]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[32]  C. Gieger,et al.  Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior , 2010, Nature Genetics.

[33]  E. Gonzalez de Mejia,et al.  Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. , 2010, Journal of food science.

[34]  Curtis D. Klaassen,et al.  Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation , 2010, Pharmacological Reviews.

[35]  S. Janković,et al.  In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population , 2010, European Journal of Clinical Pharmacology.

[36]  A. Schinkel,et al.  Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. , 2009, Advanced drug delivery reviews.

[37]  W. Daniel,et al.  The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. , 2008, Biochemical pharmacology.

[38]  A. Gunes,et al.  Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. , 2008, Pharmacogenomics.

[39]  G. Perdew,et al.  The aryl hydrocarbon receptor complex and the control of gene expression. , 2008, Critical reviews in eukaryotic gene expression.

[40]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[41]  E. Asprodini,et al.  In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. , 2007, Biomedical chromatography : BMC.

[42]  Christina N. Lessov-Schlaggar,et al.  CYP2A6 genotype and the metabolism and disposition kinetics of nicotine , 2006, Clinical pharmacology and therapeutics.

[43]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[44]  Yu-Tse Wu,et al.  Hepatobiliary excretion and brain distribution of caffeine in rats using microdialysis , 2006 .

[45]  Lars Lind,et al.  A Comparison of Three Different Methods to Evaluate Endothelium-Dependent Vasodilation in the Elderly: The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[46]  H. Yamazaki,et al.  CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS , 2005, Drug Metabolism and Disposition.

[47]  E. Ingelsson,et al.  Insulin resistance and risk of congestive heart failure. , 2005, JAMA.

[48]  N. Benowitz,et al.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.

[49]  P. Greengard,et al.  Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine , 2002, Nature.

[50]  B. Fredholm,et al.  Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. , 1999, Pharmacological reviews.

[51]  N. Benowitz,et al.  Validation of urine caffeine metabolite ratios with use of stable isotope‐labeled caffeine clearance , 1996, Clinical pharmacology and therapeutics.

[52]  F. Gonzalez,et al.  Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. , 1992, Pharmacogenetics.

[53]  D. Grant,et al.  Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[54]  W R Millington,et al.  Blood-brain barrier transport of caffeine: dose-related restriction of adenine transport. , 1982, Life sciences.

[55]  Genotype imputation and genetic association studies of UK , 2022 .